Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Gilead Sciences (NQ:GILD)

114.76 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its... 
Via StockStory
Topics Artificial Intelligence
Which S&P500 stocks are gapping on Thursday?
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed
The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy. 
Via Stocktwits
Stay informed with the top movers within the S&P500 index on Wednesday.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts
 
Via Benzinga
Gilead Sciences's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Which S&P500 stocks are gapping on Wednesday?
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding
HIV prevention is a staple in Gilead Sciences' wheelhouse. 
Via Investor's Business Daily
Wednesday's pre-market session: top gainers and losers in the S&P500 index
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements. 
Via Chartmill
P/E Ratio Insights for Gilead Sciences
 
Via Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
 
Via Benzinga
Crypto Mixed Post Trump-Putin Call; Trump Eyes HIV Program Cuts, Gilead Dips; Nvidia's AI Lead Secure Through 2028, Says JPMorgan – Top Headlines While The U.S. Slept
 
Via Benzinga
Topics Artificial Intelligence Government
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides
HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the... 
Via Benzinga
Topics Government
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
Unpacking the Latest Options Trading Trends in Gilead Sciences
 
Via Benzinga
Gilead Sciences - Leader In HIV Medicines
The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline. 
Via Talk Markets
Topics Stocks / Equities
Friday's session: top gainers and losers in the S&P500 index
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Is Gilead Sciences Gaining or Losing Market Support?
 
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) Exhibits Quality Stock Traits. Here's Why.
A fundamental analysis of (NASDAQ:GILD): Why GILEAD SCIENCES INC (NASDAQ:GILD) should be investigated by quality investors. 
Via Chartmill
Gilead Presents New HIV Treatment And Cure Research Data
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety in early HIV treatment. 
Via Benzinga
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
From Gilead Sciences, Inc.
Via Business Wire
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
From Gilead Sciences, Inc.
Via Business Wire
These 3 Dividend Stocks Jumped 15% in a Month—More to Come?
Via MarketBeat
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
Via StockStory
Topics Artificial Intelligence
The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)
Via The Motley Fool
Topics Artificial Intelligence
1 Value Stock with Exciting Potential and 2 to Ignore
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Best And Worst Performing S&P 500 Stocks Since Trump's Election Win
Financial markets volatile since Trump's 2024 election, some companies surged like Palantir while others struggled such as First Solar. 
Via Benzinga
Topics Government Stocks
Salesforce Earnings Top Views. Software Stock Falls On Weak Revenue Outlook.
Salesforce stock fell after the company's revenue guidance for fiscal 2026 came in below expectations, despite the ramp of new AI products. 
Via Investor's Business Daily
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.